Vesting of awards under Long Term Incentive Plan

RNS Number : 8787I
Hutchmed (China) Limited
21 April 2022
 

 

Vesting of awards under the Long Term Incentive Plan

 

Hong Kong, Shanghai & Florham Park, NJ - Thursday, April 21, 2022: HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan ("LTIP") on April 20, 2020 to the following persons discharging managerial responsibilities were vested on April 20, 2022:-

 

Award Holder


Number of American depositary shares ("ADS")




Mr Simon To (Executive Director)


2,3971

Dr Dan Eldar (Non-executive Director ("NED"))


2,397

Ms Edith Shih (NED)


2,3972

Mr Paul Carter (Independent Non-executive Director ("INED"))


2,0373  

Dr Karen Ferrante (INED)


2,397

Mr Graeme Jack (INED)


2,397

Professor Tony Mok (INED)


2,397

 

Notes:

(1)  Similar to the arrangement for his Director's fees, these ADSs were   not received by Mr Simon To, but were received by or for the account of his employer, Hutchison Whampoa (China) Limited.

(2)  Similar to the arrangement for her Director's fees, these ADSs were not received by Ms Edith Shih, but were received by or for the account of her employer, Hutchison International Limited.

(3)  Mr Paul Carter elected, on acceptance of the grant of his awards, to have 15% of his LTIP awards (amounting to US$7,500 with respect to his awards which vested on April 20, 2022) held on his behalf by the trustee administering the LTIP pending vesting in the form of cash, to settle his tax liabilities in respect of his awards.

 

 

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

 

(a) Dr Dan Eldar

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Dr Dan Eldar

 

2

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Director

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

HUTCHMED (China) Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

ADS each representing five Ordinary Shares of US$0.10

 

 

 

ADS ISIN: US44842L1035

 

b)

 

Nature of the transaction

 

 

Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP

 

 

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

Nil

2,397 ADS

 

d)

 

Aggregated information

-

Aggregated volume

-

Price

 

N/A

 

e)

 

Date of the transaction

 

2022-04-20

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

(b) Mr Paul Carter

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Mr Paul Carter

 

2

Reason for the notification

 

a)

 

Position/status

 

Independent Non-Executive Director

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

HUTCHMED (China) Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

ADS each representing five Ordinary Shares of US$0.10

 

 

 

ADS ISIN: US44842L1035

 

b)

 

Nature of the transaction

 

 

Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP

 

 

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

Nil

2,037 ADS

 

d)

 

Aggregated information

-

Aggregated volume

-

Price

 

N/A

 

e)

 

Date of the transaction

 

2022-04-20

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

(c) Dr Karen Ferrante

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Dr Karen Ferrante

 

2

Reason for the notification

 

a)

 

Position/status

 

Independent Non-Executive Director

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

HUTCHMED (China) Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

ADS each representing five Ordinary Shares of US$0.10

 

 

 

ADS ISIN: US44842L1035

 

b)

 

Nature of the transaction

 

 

Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP

 

 

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

Nil

2,397 ADS

 

d)

 

Aggregated information

-

Aggregated volume

-

Price

 

N/A

 

e)

 

Date of the transaction

 

2022-04-20

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 



 

(d) Mr Graeme Jack

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Mr Graeme Jack

 

2

Reason for the notification

 

a)

 

Position/status

 

Independent Non-Executive Director

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

HUTCHMED (China) Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

ADS each representing five Ordinary Shares of US$0.10

 

 

 

ADS ISIN: US44842L1035

 

b)

 

Nature of the transaction

 

 

Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP

 

 

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

Nil

2,397 ADS

 

d)

 

Aggregated information

-

Aggregated volume

-

Price

 

N/A

 

e)

 

Date of the transaction

 

2022-04-20

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

(e) Professor Tony Mok

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Professor Tony Mok

 

2

Reason for the notification

 

a)

 

Position/status

 

Independent Non-Executive Director

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

HUTCHMED (China) Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

ADS each representing five Ordinary Shares of US$0.10

 

 

ADS ISIN: US44842L1035

 

b)

 

Nature of the transaction

 

 

Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP

 

 

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

Nil

2,397 ADS

 

d)

 

Aggregated information

-

Aggregated volume

-

Price

 

N/A

 

e)

 

Date of the transaction

 

2022-04-20

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of about 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

 

CONTACTS

Investor Enquiries


Mark Lee, Senior Vice President

+852   2121   8200

Annie Cheng, Vice President

+1   (973)   567   3786



Media Enquiries

 

Americas - Brad Miles,
Solebury Trout

+1   (917)   570   7340   (Mobile)
bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw,
FTI Consulting

+44   20   3727   1030 / +44   7771   913   902   (Mobile) / +44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com

Asia - Zhou Yi,
Brunswick

+852   97 83   6894   (Mobile)
HUTCHMED@brunswickgroup.com



Nominated Advisor


Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited

+44   (20)   7886   2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGLGDSXSDDGDB
UK 100

Latest directors dealings